Baseline factors associated with glycaemic response to treatment with once-weekly dulaglutide in patients with type 2 diabetes.

Wysham C, Guerci B, D'Alessio D, Jia N, Botros FT

Diabetes, obesity & metabolism12 Jul 2016Cited by 21 (Europe PMC)

PMID27265893DOI10.1111/dom.12702PepBankPUB-27265893

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone10

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

01HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
Baseline HbA1c had the largest relative influence on HbA1c reduction during dulaglutide treatment.
In plain wordsHigher starting HbA1c was linked to a larger HbA1c reduction during dulaglutide treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableBaseline HbA1c influence
Study
n = 2,806
Outcome group
Glycemic control · Metabolic and weight
Measurements
Relative influence
48.8%
baseline HbA1c
Source sentences
Summary
The gradient-boosting analysis showed that the top influential baseline factors associated with HbA1c reduction were: HbA1c (48.8%), age (9.1%), fasting serum glucose (FSG; 8.2%), fasting serum insulin (FSI; 6.7%) and estimated glomerular filtration rate (eGFR; 5.4%).
1 context sentence(design, population, supporting numbers)
Summary · context
Baseline covariates from patients receiving dulaglutide in six phase III studies (n = 2806) were analysed using a gradient-boosting method to assess their relative influence on the change in HbA1c after 26 weeks of treatment.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2726589301
02HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
Baseline age had 9.1% relative influence on HbA1c reduction during dulaglutide treatment.
In plain wordsStarting age was linked to the HbA1c response during dulaglutide treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableAge influence
Study
n = 2,806
Outcome group
Glycemic control · Metabolic and weight
Measurements
Relative influence
9.1%
age
Source sentences
Summary
The gradient-boosting analysis showed that the top influential baseline factors associated with HbA1c reduction were: HbA1c (48.8%), age (9.1%), fasting serum glucose (FSG; 8.2%), fasting serum insulin (FSI; 6.7%) and estimated glomerular filtration rate (eGFR; 5.4%).
1 context sentence(design, population, supporting numbers)
Summary · context
Baseline covariates from patients receiving dulaglutide in six phase III studies (n = 2806) were analysed using a gradient-boosting method to assess their relative influence on the change in HbA1c after 26 weeks of treatment.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2726589302
03HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
Baseline fasting serum glucose had 8.2% relative influence on HbA1c reduction during dulaglutide treatment.
In plain wordsStarting fasting blood sugar was linked to the HbA1c response during dulaglutide treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableFasting serum glucose influence
Study
n = 2,806
Outcome group
Glycemic control · Metabolic and weight
Measurements
Relative influence
8.2%
FSG
Source sentences
Summary
The gradient-boosting analysis showed that the top influential baseline factors associated with HbA1c reduction were: HbA1c (48.8%), age (9.1%), fasting serum glucose (FSG; 8.2%), fasting serum insulin (FSI; 6.7%) and estimated glomerular filtration rate (eGFR; 5.4%).
1 context sentence(design, population, supporting numbers)
Summary · context
Baseline covariates from patients receiving dulaglutide in six phase III studies (n = 2806) were analysed using a gradient-boosting method to assess their relative influence on the change in HbA1c after 26 weeks of treatment.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2726589303
04HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
Baseline fasting serum insulin had 6.7% relative influence on HbA1c reduction during dulaglutide treatment.
In plain wordsStarting fasting insulin was linked to the HbA1c response during dulaglutide treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableFasting serum insulin influence
Study
n = 2,806
Outcome group
Glycemic control · Metabolic and weight
Measurements
Relative influence
6.7%
FSI
Source sentences
Summary
The gradient-boosting analysis showed that the top influential baseline factors associated with HbA1c reduction were: HbA1c (48.8%), age (9.1%), fasting serum glucose (FSG; 8.2%), fasting serum insulin (FSI; 6.7%) and estimated glomerular filtration rate (eGFR; 5.4%).
1 context sentence(design, population, supporting numbers)
Summary · context
Baseline covariates from patients receiving dulaglutide in six phase III studies (n = 2806) were analysed using a gradient-boosting method to assess their relative influence on the change in HbA1c after 26 weeks of treatment.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2726589304
05HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
Baseline eGFR had 5.4% relative influence on HbA1c reduction during dulaglutide treatment.
In plain wordsStarting kidney filtration was linked to the HbA1c response during dulaglutide treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableeGFR influence
Study
n = 2,806
Outcome group
Glycemic control · Metabolic and weight
Measurements
Relative influence
5.4%
eGFR
Source sentences
Summary
The gradient-boosting analysis showed that the top influential baseline factors associated with HbA1c reduction were: HbA1c (48.8%), age (9.1%), fasting serum glucose (FSG; 8.2%), fasting serum insulin (FSI; 6.7%) and estimated glomerular filtration rate (eGFR; 5.4%).
1 context sentence(design, population, supporting numbers)
Summary · context
Baseline covariates from patients receiving dulaglutide in six phase III studies (n = 2806) were analysed using a gradient-boosting method to assess their relative influence on the change in HbA1c after 26 weeks of treatment.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2726589305
06HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
Higher baseline HbA1c was associated with greater HbA1c reduction during dulaglutide treatment in multivariable regression.
In plain wordsHigher starting HbA1c was linked to greater HbA1c reduction during dulaglutide treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c response by baseline HbA1c
Study
n = 2,806
Outcome group
Glycemic control · Metabolic and weight
Measurements
Coefficient estimate
−0.6%
baseline HbA1c
Coefficient estimate
−6.6 mmol/mol
baseline HbA1c
Source sentences
Summary
Multivariable regression showed that higher baseline HbA1c was the major factor associated with greater HbA1c reduction [coefficient estimates: -0.6% (-6.6 mmol/mol); p < 0.0001].
1 context sentence(design, population, supporting numbers)
Summary · context
Baseline covariates from patients receiving dulaglutide in six phase III studies (n = 2806) were analysed using a gradient-boosting method to assess their relative influence on the change in HbA1c after 26 weeks of treatment.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2726589306
07HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
Age at or below 65 years was associated with a very small additional HbA1c decrease during dulaglutide treatment.
In plain wordsAge at or below 65 years was linked to a slightly larger HbA1c decrease during dulaglutide treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c response by age
Study
n = 2,806
Outcome group
Glycemic control · Metabolic and weight
Measurements
Coefficient estimate range
−0.05 to −0.2%
range reported jointly for age <=65 years, lower FSG, FSI <=55 pmol/L and eGFR <=100 mL/min/1.73 m2
Coefficient estimate range
−0.6 to −2.2 mmol/mol
range reported jointly for age <=65 years, lower FSG, FSI <=55 pmol/L and eGFR <=100 mL/min/1.73 m2
Source sentences
Summary
Age ≤65 years, lower FSG level, FSI level ≤55 pmol/L and eGFR ≤100 mL/min/1.73 m² were associated with greater decreases in HbA1c, but the effect was very small [coefficient estimates: -0.05% to -0.2% (-0.6 to -2.2 mmol/mol)].
1 context sentence(design, population, supporting numbers)
Summary · context
Baseline covariates from patients receiving dulaglutide in six phase III studies (n = 2806) were analysed using a gradient-boosting method to assess their relative influence on the change in HbA1c after 26 weeks of treatment.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2726589307
08HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
Lower baseline fasting serum glucose was associated with a very small additional HbA1c decrease during dulaglutide treatment.
In plain wordsLower starting fasting blood sugar was linked to a slightly larger HbA1c decrease during dulaglutide treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c response by fasting glucose
Study
n = 2,806
Outcome group
Glycemic control · Metabolic and weight
Measurements
Coefficient estimate range
−0.05 to −0.2%
range reported jointly for age <=65 years, lower FSG, FSI <=55 pmol/L and eGFR <=100 mL/min/1.73 m2
Coefficient estimate range
−0.6 to −2.2 mmol/mol
range reported jointly for age <=65 years, lower FSG, FSI <=55 pmol/L and eGFR <=100 mL/min/1.73 m2
Source sentences
Summary
Age ≤65 years, lower FSG level, FSI level ≤55 pmol/L and eGFR ≤100 mL/min/1.73 m² were associated with greater decreases in HbA1c, but the effect was very small [coefficient estimates: -0.05% to -0.2% (-0.6 to -2.2 mmol/mol)].
1 context sentence(design, population, supporting numbers)
Summary · context
Baseline covariates from patients receiving dulaglutide in six phase III studies (n = 2806) were analysed using a gradient-boosting method to assess their relative influence on the change in HbA1c after 26 weeks of treatment.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2726589308
09HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
Fasting serum insulin at or below 55 pmol/L was associated with a very small additional HbA1c decrease during dulaglutide treatment.
In plain wordsLower starting fasting insulin was linked to a slightly larger HbA1c decrease during dulaglutide treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c response by fasting insulin
Study
n = 2,806
Outcome group
Glycemic control · Metabolic and weight
Measurements
Coefficient estimate range
−0.05 to −0.2%
range reported jointly for age <=65 years, lower FSG, FSI <=55 pmol/L and eGFR <=100 mL/min/1.73 m2
Coefficient estimate range
−0.6 to −2.2 mmol/mol
range reported jointly for age <=65 years, lower FSG, FSI <=55 pmol/L and eGFR <=100 mL/min/1.73 m2
Source sentences
Summary
Age ≤65 years, lower FSG level, FSI level ≤55 pmol/L and eGFR ≤100 mL/min/1.73 m² were associated with greater decreases in HbA1c, but the effect was very small [coefficient estimates: -0.05% to -0.2% (-0.6 to -2.2 mmol/mol)].
1 context sentence(design, population, supporting numbers)
Summary · context
Baseline covariates from patients receiving dulaglutide in six phase III studies (n = 2806) were analysed using a gradient-boosting method to assess their relative influence on the change in HbA1c after 26 weeks of treatment.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2726589309
10HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
eGFR at or below 100 mL/min/1.73 m² was associated with a very small additional HbA1c decrease during dulaglutide treatment.
In plain wordsLower starting kidney filtration was linked to a slightly larger HbA1c decrease during dulaglutide treatment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c response by eGFR
Study
n = 2,806
Outcome group
Glycemic control · Metabolic and weight
Measurements
Coefficient estimate range
−0.05 to −0.2%
range reported jointly for age <=65 years, lower FSG, FSI <=55 pmol/L and eGFR <=100 mL/min/1.73 m2
Coefficient estimate range
−0.6 to −2.2 mmol/mol
range reported jointly for age <=65 years, lower FSG, FSI <=55 pmol/L and eGFR <=100 mL/min/1.73 m2
Source sentences
Summary
Age ≤65 years, lower FSG level, FSI level ≤55 pmol/L and eGFR ≤100 mL/min/1.73 m² were associated with greater decreases in HbA1c, but the effect was very small [coefficient estimates: -0.05% to -0.2% (-0.6 to -2.2 mmol/mol)].
1 context sentence(design, population, supporting numbers)
Summary · context
Baseline covariates from patients receiving dulaglutide in six phase III studies (n = 2806) were analysed using a gradient-boosting method to assess their relative influence on the change in HbA1c after 26 weeks of treatment.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-2726589310

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.